 IDEAYA Biosciences, Inc. NASDAQ:IDYA, an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, announced First-Patient-In FPI in the Phase 1 combination study of IDE196 and binimetinib, a MEK inhibitor, in metastatic uveal melanoma MUM. The clinical combination of IDE196 and binimetinib is being evaluated by IDEAYA with binimetinib being supplied by Pfizer pursuant to a clinical trial collaboration and supply agreement. 